Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
about
Hypoxia-inducible factors and the response to hypoxic stressHypoxic signaling during tissue repair and regenerative medicineCompensatory angiogenesis and tumor refractorinessRole of hypoxia-inducible factors in breast cancer metastasisCancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasisNovel insights into the molecular origins and treatment of lung cancerHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsSilencing prion protein in MDA-MB-435 breast cancer cells leads to pleiotropic cellular responses to cytotoxic stimuliBile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell modelsDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsHypoxia as a target for drug combination therapy of liver cancer.Sustained delivery of a HIF-1 antagonist for ocular neovascularization.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.Development of HIF-1 inhibitors for cancer therapyThe effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing micePotent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Micellar electrokinetic chromatographic analysis for in vitro accumulation of anthracyclines enhanced by inhibitors of cell membrane transporter-proteins in cancer cells.Hypoxia potentiates glioma-mediated immunosuppressionMolecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targetsSe-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLIdentification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenograftsThe antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.Quantifying the vascular response to ischemia with speckle variance optical coherence tomographyAnti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxiaModulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.The role of the HIF-1α transcription factor in increased cell division at physiological oxygen tensions.Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaRemodeling Characteristics and Collagen Distributions of Biologic Scaffold Materials Biopsied From Postmastectomy Breast Reconstruction Sites.Suppression of the hypoxia inducible factor-1 function by redistributing the aryl hydrocarbon receptor nuclear translocator from nucleus to cytoplasm.The impact of chemotherapy and radiation therapy on the remodeling of acellular dermal matrices in staged, prosthetic breast reconstruction.Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersAnalysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature
P2860
Q24629323-BA8173D9-60E7-40B3-9C1D-D4EE18352DB8Q26824402-134A4499-27C4-412A-ADBD-BD3E8A4DDEC4Q26851916-89EF70DC-263B-40B7-A3EC-9ADDE56CE653Q26860122-CDA1CD57-8BBB-4790-86CB-EAD77ACAFC1AQ26866144-9320632A-1752-4073-B519-827E239B1E57Q28386773-9A4935FF-113F-47AB-9CEC-91B3983C0CAEQ28393898-359B0233-2A41-4D78-BF19-EA603DE9B389Q28484842-6B87C256-EC53-463C-8941-AC35705EC28FQ28596213-24CDDBB3-045A-4DA2-9E24-C62DA5A02149Q29615944-BDD2AAB2-DCDF-48D0-9008-48503B85AE34Q30491780-4D6B95DA-61E6-4CAB-992F-1E3D78646331Q30560557-8350DBD6-207C-4C8F-BD2B-3ACA31124C1BQ33420436-CBDE5FDC-1678-4817-BC03-646A0906AFB5Q33618312-F8C02CE7-4A0F-4580-8C14-33825032C9D8Q33703381-76F4125E-62A9-4C79-AE24-134693234695Q33713934-36AF209F-0251-4BE9-A5C2-C5A8B426096BQ33780751-23616762-4DCD-4DBE-8D5F-659137072C5AQ33795090-31E3267C-CE4C-4D4B-9EE4-368051957AA8Q33809268-6E8D95F0-7EB4-4BD2-8CF5-4E5FD23E840CQ34023663-CC34A347-51CB-44C7-AA0A-E1A44A95BF7CQ34047866-F6018488-0F7E-4BDB-B6B4-09264C55105FQ34267974-DA5C7554-EF95-410B-BE65-B89A12E8D33BQ34402836-D0D411E1-DFFF-4F4E-BCB1-FF8EFD948CB7Q34587649-A0328C03-B549-449D-8344-E0E6614FA642Q34672437-2D87A836-3E6E-4403-B200-E4B9FC759071Q34805346-F5ED3C06-3AE1-4322-B6AD-1402F35A4B00Q34848606-50EF66EC-ECDC-41BF-AE7C-9C29249B3DE5Q34992476-8EBA0C9C-9C47-45B9-AB4C-EF88BCBEAD96Q35158082-B39A676D-B2D6-4897-A703-792C0D9C4CBEQ35163974-CC02A78A-9B88-41C1-A2B9-08E7F64EFA78Q35169937-7BAAB128-818C-4071-8790-46ED499177C2Q35448249-9586CF7E-83A2-4B81-97E2-A8623B63606EQ35559050-1411499B-9B8D-410A-A227-C14842697ABCQ35660360-0764454A-2161-41D8-A79C-BA389AAC2CD4Q35738624-43BB0E9B-50CD-4023-801D-F35F665DCC3BQ35871828-F8E861CB-E47B-45A0-95AE-6A7116513E01Q35889011-051E4C29-EF3F-45EC-B438-3F420696FDE1Q35918752-E0DEEB99-584B-4BB4-B6B6-CDDA9026A0E4Q35966821-B400C931-DC55-4EB0-85C1-B43D9B053D89Q36027155-C20A3875-DD51-45A3-B620-B312B82B3C1E
P2860
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@ast
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@en
type
label
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@ast
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@en
prefLabel
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@ast
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@en
P2093
P2860
P356
P1476
Anthracycline chemotherapy inh ...... f circulating angiogenic cells
@en
P2093
David Z Qian
KangAe Lee
Sergio Rey
P2860
P304
P356
10.1073/PNAS.0812801106
P407
P577
2009-01-23T00:00:00Z